Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axatilimab Phase 1/2 in active cGVHD
NCT03604692Phase 2Completed
- Sponsor
- Syndax Pharmaceuticals
- Start
- Nov 2018
- Primary completion
- Aug 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of axatilimab in chronic graft-versus-host disease (cGVHD), sponsored by Syndax Pharmaceuticals. Started Nov 2018; status: completed.
02
Drugs
axatilimab
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT03604692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03604692.